Low-dose liposomal iron (17-34 mg elemental/day) was compared with standard conventional oral iron (100-200mg elemental/day) in the treatment of iron deficiency anemia following sleeve gastrectomy. Liposomal iron provided superior hematological improvement and gastrointestinal tolerance.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
* Age between 18 and 65 years
* History of laparoscopic sleeve gastrectomy performed at least 6 months prior to enrollment
* Diagnosis of iron deficiency anemia, defined as:
* Hemoglobin \<12 g/dL in women or \<13 g/dL in men, and
* Serum ferritin \<30 ng/mL or transferrin saturation (TSAT) \<20%
* Mild to moderate anemia (hemoglobin ≥9 g/dL)
* Ability to take and swallow oral medications
* Willingness to participate and provide written informed consent Exclusion Criteria
* Active gastrointestinal disease (e.g., inflammatory bowel disease, peptic ulcer disease, or gastrointestinal bleeding)
* Chronic kidney disease with estimated GFR \<30 mL/min/1.73 m²
* Use of oral or parenteral iron, vitamin B12, or folate supplementation within the previous 3 months
* Iron overload or hemochromatosis (serum ferritin \>300 ng/mL)
* Known allergy or intolerance to iron preparations
* Active malignancy
* Pregnancy or breastfeeding
* Known hemoglobinopathies (e.g., thalassemia, sickle cell disease)
* Blood transfusion within the previous 1 month
* Cognitive or psychiatric disorder interfering with study participation or protocol adherence
What they're measuring
1
Change in Hemoglobin Level From Baseline to Week 24